Carl Gelhaus

Carl Gelhaus has an extensive work experience. Carl is currently the Director of Nonclinical Research at Appili Therapeutics since December 2022. Previously, they founded Full Effect Biotech, Inc. in 2018 and served as the President & CEO, focusing on drug repurposing. Carl Gelhaus has also worked as an Adjunct Professor at the University of Missouri-Kansas City since July 2015 and at the Kansas City University of Medicine and Biosciences since October 2015. Carl was also the Director at Ars Biotechnica, Inc. since August 2013.

Before that, Gelhaus had multiple roles at MRIGlobal, including Principal Scientist from October 2020 to October 2022, Senior Program Manager from January 2017 to September 2020, and Principal Scientist from July 2013 to January 2017. Carl was an Adjunct Assistant Professor at Wright State University from 2011 to July 2013 and a Principal Research Scientist at Battelle from May 2008 to June 2013. Carl Gelhaus started their career as a Post-doctoral Fellow at USAMRIID and as a Molecular Biology Database Curator at Addeco Technologies in 2005.

Carl Gelhaus completed their Bachelor's degree in Biology from the University of Cincinnati from 1994 to 1998. Carl then pursued further education at the University of Colorado Anschutz Medical Campus, where they obtained their Doctor of Philosophy (Ph.D.) in Microbiology and Immunology between 1998 and 2004.